early-stag handicap remdesivir clinic trial
post posit bounc follow
respons data matur
hard time requir hard choic reduc invest
miss guidanc pull capit rais
forc estim pt chang
fda late june
pre-releas revenu pull guidanc
takeaway discuss manag
delay respect net posit focus
complet target treatment studi
analyst certif import disclosur see
impress data valid patrol platform pt
physician tepid tazverik upcom fl launch downgrad
perform
impact forc estim chang downgrad
impact like signific downgrad under-perform
brace step-down number
pandem edit cell therapi timelinecatalyst remain
quarterli updat shed light vaccin plan
stick guidanceat least til updat
opportun expand pna platform
eas regul health/hospic benefit
tactic move sidelin
gut feel say extend develop timelin pt
takeaway discuss manag
maintain perform posit prevent lower pt
updat virtual posit renal denerv data
tool assess pandem impact trial within coverag
data continu showcas tavr benefit
takeaway discuss manag
takeaway kol discuss impact
pandem influenc program mix bag
top stori week temporarili eas number rule regul order increas flexibl provid
deal home health compani rule temporarili allow telehealth part overal plan care
patient longer limit homebound statu hospit chang allow provid move
patient makeshift off-sit locat increas usag non-physician provid care much-anticip rule cover
mani differ compon health care system view increas role home-bas provid
early-stag handicap remdesivir clinic trial
gilead report hand remdesivir trial result next week compani regist
trial on-going see two phase trial investigator-sponsor china anoth two phase trial
sponsor locat world-wide remdesivir demonstr potent vitro efficaci rna virus
cell-bas assay evid efficaci california washington state anecdot evid
cruis ship japanes patient treat japan believ in-vitro data robust limit data
human patient nuanc due patient present lead us cautiou go impend data
post posit bounc follow disrupt
pre-announc revenu growth impli total revenu line estim
consensu compani also withdrew prior financi guidanc revenu
remain one top idea potenti rebound follow end disrupt healthcar system relat
expect sharp contract demand maci anticip much demand
recaptur younger patient larg cartilag defect view surgic procedur necessari
maci remain gold standard durabl reduct pain improv knee function
announc potenti acceler us approv pathway padcev keytruda advanc urotheli cancer
patient unabl receiv cisplatin-bas chemotherapi muc popul consist cisplatin-inelig patient
 elig patient potenti acceler approv larg popul meaning acceler
timelin sgen/astella updat result ev keytruda feb note orr
earli profil chemo -free regimen look compel vs competit insid updat model
acceler cisplatin-inelig launch also lower adcetri sale slightli
guidanc account disrupt maintain
anthracyclin cohort demonstr clean cardio tox wait respons data matur
mbrx report posit safeti updat phase develop next-gener anthracyclin annamycin
compani disclos dose patient last updat includ subject european cohort
evid cardiotox believ annamycin continu demonstr differenti safeti profil
mg/m repres exposur fda cumul maximum anthracyclin exposur
whether higher exposur translat better clinic respons aml patient primari question investor
address next month mbrx complet dose follow cohort
hard time requir hard choic reduc invest growth reshap invest outlook
pre-announce revenu estim withdrew financi
guidanc due announc hire freez intent reduc growth oper expens initi
equiti offer cut pt account dilut like multipl contract transit
bia toward revenu growth focu profit manag note sharp drop demand second half march
provid metric assess magnitud headwind updat forecast assum reduct
reduct volum prior outlook increas net loss expect cost
reduct match rapid revenu deceler
miss guidanc pull capit rais announc
market close yesterday april pre-announc preliminari number simultan withdrew
guidanc impact updat number yesterday morn number lower
vs prior estim consensu highlight note date tier categori
procedur base guidelin impli troubl procedur volum updat number reflect
compani pre-announc howev fundament worri thing might get far wors gener henc
forc estim pt chang
situat forc us revis estim downward rate remain pt adjust
vs prior use multipl sale fundament concern remain ua therapi osa
second-lin therapi behind cpap much smaller factor consensu view real-world outcom
ua reflect outcom definit success problemat high cost busi stock
ytd vs continu believ disconnect expect realiti
snapshot overenthusiast expect shown forward p/ graph exhibit page
fda late june
previous guid acst submit meet request fda follow complet audit trilog site
central lab meet anticip second half june acst intend seek fda feedback
interpret data propos amend statist analysi plan propos pool
data support nda discuss manag yesterday indic clear understand key driver behind
high placebo respons center around enrol deviat site meet minut becom avail
acst end juli remain cautious optimist capr approv without addit clinic studi
asnd report net loss vs mainli higher lower financ incom asnd provid
pipelin updat remain focus top-lin data phase path forward trial hypoparathroid
slate mid-april first look six-month ole data studi anticip compani remain track
submit transcon hgh bla pghd respect yesterday report seen littl
impact although transcon phase enrol may somewhat slower expect least
short term remain bullish ascendi transform pipelin reiter outperform head path
pre-releas revenu pull guidanc
close pre-releas rev slightli prior guidanc
estim consensu also withdraw prior guidanc given uncertainti
also fulli drew revolv detail compani note product two four postpon
procedur categori cmss recent guidanc concur rel name coverag
use less discretionari procedur ought weather storm better bounc back sooner wrote
note brace step-down number like coil spring thing normal
takeaway discuss manag
discuss potenti near-term impact busi outlook manag key takeaway
nuplazid sale perform rel well despit salesforc switch virtual mode specialti
pharmaci enabl home deliveri although lower estim assum fewer new patient start drp snda
submiss remain track summer expect prioriti review given btd note undisrupt
commun fda mdd rhett syndrom trial remain on-going although enrol new patient
temporarili paus sn pivot initi could delay beyond advantag peer kol event
highlight unmet need continu assess bd opportun remain well-posit
delay respect net posit focus complet target treatment studi
market close cdtx disclos initi respect prophylaxi studi rezafungin delay begin
enrol patient disclosur larg line expect outlin march note view
net posit cdtx view prophylaxi attract commerci opportun rezafungin account
two-third peak revenu forecast base potenti once-weekli echinocandin address
grow problem azol resist critic path fda approv rezafungin complet phase restor
candidiasi treatment studi alreadi push back late view like face
continu enrol headwind relat
peer analog show initi efficaci nash via surrog mri-pdff see favor read-
across addit valid moa long-act glycopegyl analog
fusion protein balanc studi nash patient
test weekli inject three dose vs placebo interim mri-pdff show strong stat sig
reduct week placebo rel reduct respons rate
dose group also show dose depend reduct alt histolog data avail
howev consid unusu low placebo respons rate data may placebo control
impress data valid patrol platform pt
follow impress preclin result slide financi result updat model
nbse rais pt promis pharmacokinet pk data non-human primat nhp in-vitro
pharmacodynam pk data patient-deriv huntington cell line nbse competit edg hd
valid also see opportun beyond hd patrol platform could potenti
gener non-dilut fund opportun collabor believ nbse continu stay disciplin focu
move hd clinic time frame remain focus compani execut addit pd
studi lead candid select ind-en studi stay bullish
physician tepid tazverik upcom fl launch downgrad perform
approach tazverik anticip approv follicular lymphoma pdufa expect stock
perform key launch indic consult call recent held two key opinion
leader hematology-oncolog express lukewarm sentiment tazverik uptak given efficaci view modest
despit oral dose rel benign toler follow lower revenu project moder
consensu specialist also express limit enthusiasm adopt w/revlimid-rituxan r-squar
investig global confirmatori trial tazverik clinic investig cancer early-stag
rest pipelin downgrad perform pt temper convict around tazverik fl launch
impact forc estim chang downgrad
downgrad under-perform perform pt newli
establish pt repres sale estim vs prior estim fundament view
ivl lithotripsi good tool clinician armamentarium treat cad pad howev expect
increment util ivl misplac highlight initi report date recent field check continu
paint tough pictur number compani space shockwav high multipl combin impact
procedur slowdown forc us downgrad stock
updat model reflect ortx announc potenti relat impact regulatori clinic
timelin lower sale estim strimv due treatment delay milan itali treatment site
assum ada-scid us launch late vs earli mld us launch mid-to-l vs earli
eu launch separ lower capital-expenditure increas spend due temporari hold
manufactur facil buildout fremont ca lower pt due chang higher wacc
vs maintain outperform rate note ortx pipelin catalyst provid meaning upsid potenti
impact like signific downgrad under-perform
downgrad intuit surgic under-perform rate perform pt newli
establish pt repres sale estim vs prior estim fundament view
alway robot surgeri good tool complex surgeri howev rapid prolifer benign case driven
aggress market rather true clinic util recent field check continu paint tough pictur
number compani space intuit top list primari reason downgrad impact
capit sale procedur volum pressur hospit margin longer expect time
drastic lower estim account current uncertainti around hospit around
us remain deep freez mention industri note date cautiou probabl
quick v-shape rebound problem procedur truli elect natur defer
long time unlik edward lifesci compound natur procedur high expect
set believ requir recalibr shortli
drastic lower estim account current uncertainti around hospit around
us remain deep freez mention industri note date cautiou probabl
quick v-shape rebound mitig factor edward life-threaten procedur mortal
sever symptomat patient within year henc edward core tavr growth expect rebound
rel quickli howev prudenc dictat acknowledg ding volum short medium
term estim chang accordingli outperform rate unchang ew remain top pick
brace step-down number
recent revers stock multipl view base emot fundament consensu wisdom
recoveri go v-shape advis caution field check indic short- medium-term
disloc impact space heavili residu effect could linger next year question remain
unansw private-pay elect surgeri trend rapid step-up unemploy hospit margin
razor thin relief packag enough procedur come back year get push next year
extend shutdown spain affect procedur volum given signific hub behind germani franc
surgeri final reliabl forward estim
pandem edit cell therapi timelinecatalyst remain track
expect crsp issu updat regard epidem impact on-going trial compani continu
enrol hemoglobinopathi scd -thalassemia condit dose new patient halt
disclos addit patient beyond two patient data dose cell therapi elect therapi
discuss kol highlight therapi requir icu capac current limit treatment
condit expos patient unnecessari infect risk data updat still expect oncolog cart trial
 still enrol dose delay tabl crsp site lie mainli outsid major
quarterli updat shed light vaccin plan
imv tsx also trade provid busi updat includ continu progress toward fda collabor
plan registr studi dpx survivac dlbcl ovarian cancer conting effort maintain continu
on-going clinic trial expect present updat result basket studi addit
detail work done vaccin imv leverag strength platform develop dpx-base
vaccin imv explor epitop optim immunogen collabor expert valid safeti
potenc preclin model studi healthi volunt design discuss april
health canada encourag updat
stick guidanceat least til updat
yesterday spoke manag gaug pandem impact iovanc oper busi
outlook compani stand firm prior guidanc regard key upcom mileston includ present top-
line registr data lifileucel despit loom pandemic-rel concern manag affirm patient
continu receiv tumor infiltr lymphocyt til therapi still expect pivot trial cervic cancer complet
enrol schedul view resource-intens cell therapi trigger seriou inevit slow
paus certain site least month howev iovanc til therapi test patient
remain option expect continu demand even peak us reiter outperform pt
opportun expand pna platform
today neubas nbse announc key preclin data valid novel patrol platform provid updat call
data includ pharmacokinet pk data non-human primat nhp vitro pharmacodynam pk data
patient-deriv huntington cell line believ data support thesi advantag nbse pna
tradit antisens oligonucleotid candid emerg profil select knockdown mutant huntington gene
mhtt coupl broad cell permeability/uptak tissu distribut includ sustain increas deep brain region
data support huntington diseas hd myoton dystrophi type develop nbse
expect nomin lead candid seri pd activ studi move expediti toward
eas regul health/hospic benefit
temporarili eas number rule regul order increas flexibl deal home
health compani rule temporarili allow telehealth part overal plan care patient
longer limit homebound statu hospit chang allow provid move patient makeshift off-sit
locat increas usag non-physician provid care much-anticip rule cover mani differ compon
health care system view increas role home-bas provid play bottom line
posit home-bas provid
mot report net loss compar our/consensu estim call management note
commerci launch track prior placement major us hospit gi physician train
estim higher-volum hospit mot engag hospit grow schedul
pure-vu evalu march mot also receiv ce mark approv provid access inpati
annual colonoscopi europ ww procedur management implement cost reduct
plan given anticip hospit disrupt inpati colonoscopi capit purchas program expect
complet extend compani financi runway
judg miranda du rule vascepa patent claim invalid come neg surpris although amrn intend
appeal decis significantli reduc expect around product market exclus period see revers
unlik put gener launch best case amrn yet despit presum injunct at-risk launch
could occur much sooner pend anda approv case believ vascepa heavily-trunc exclus prior
expect meaning impair amrn opportun cash flow gener effect remov amrn
appeal prospect acquir share indic open remov price target upgrad
perform expect share subsequ trade line market
cloud outlook compani pull guidanc tactic move sidelin
downgrad venu concept perform outperform price target vacat
situat forc compani pull guidanc therefor leav level uncertainti number believ
ceo believ busi model howev current uncertainti outlook forc us tactic move
sidelin wait till environ stabil glimmer hope ou front us market remain
deep freez reason drastic reduct estim
gut feel say extend develop timelin pt
monday sere announc complet enrol ecospor trial discuss impact
pandem product develop timelin manag unsurprisingli pandem neg impact
recruit across compani trial sere cap enrol ecorspor slightli short goal ensur
top-lin data could deliv per manag nearli enrol patient assess efficaci
suggest pandem unlik caus larg gap follow-up data howev believ could
substanti impact eco-reset trial enrol specul could extend
develop timelin month adjust estim accordingli reiter outperform pt
kol harri hull share view vaccin target profil prospect like acip requir dr
hull former vote member acip influenza work group
takeaway discuss manag
discuss potenti near-term impact manag key takeaway pbc sale
perform rel well despit expect gener line nash launch prepar
remain underway addit sale rep reconfirm adj opex guidanc
fda adcomm date push back prev pdufa date remain
conserv expect nash sale start lower sale forecast may opt soft-launch
oca provid virtual educ ship starter-kit delay full-scal launch revers
regener trial remain on-going although pois enrol paus view well-posit detail insid
maintain perform posit prevent lower pt
announc nurtec-odt met primari endpoint reduct monthli migrain day statist signific
howev placebo-adjust respons rate came expect day vs day see prior analysi
anticip label expans includ prevent could increment increas sale howev believ near-
medium-term address market continu acut migrain patient includ may benefit frequent
dose on-demand sub-seg increas sale vs grow vs
time maintain perform rate lower pt vs reflect higher weight averag cost capit
vs believ accur reflect risk relat current oper environ
mdwd announc suspens escharex phase ii enrol due importantli manag
reiter bla file nexobrid continu plan forecast juli unchang continu view us approv
launch nexobrid partner primari near-term opportun valu creation furthermor
nexobrid expand access protocol continu enrol patient mdwd manufactur facil continu oper
adequ suppli least next sever quarter last manag note full-year procur guidanc barda
unchang time deliveri may impact revis forecast timelin time bias
toward larger portion annual barda procur slip interim updat escharex phase ii studi
slip end await detail updat manag reivis outlook
updat virtual posit renal denerv data
yesterday scientif session report posit data spyral htn-off pivot
trial assess simplic spyral renal denerv system treatment uncontrol high blood pressur data
show statist signific reduct blood pressur baselin three month superior sham one
three long-term larg opportun along surgic robot mitral valv replac believ remain upsid
driver file year away given need spyral htn-on trial complet announc
fda breakthrough-devic design help approv timelin see renal denerv opportun
focu yesterday call manag provid comment impact seen date
manag note like outsiz impact includ march april typic includ
fiscal year-end larg order encouragingli manag note china procedur start come back though still y/
overal visibl end-market condit remain low near-term solid balanc sheet/cash flow convers
near-term support compani pipelin numer driver focu medium/long-term
tool assess pandem impact trial within coverag
discuss impact oncolog practic clinic trial sever kol oncolog practic
trial conduct impact substanti risk infect enter equat trial risk/benefit
analysi trial still enrol despit skeleton crew driven drug deem viabl option late line patient
prefer given oral vs iv agent demonstr efficaci potenti signific benefit soc trial
intervent long hospit stay incl cart bmt biopsi intens pk/pd work includ sad mad trial
delay site analyz oncolog trial clinicaltri gov develop excel document avail
upon request gaug impact trial burden specif geographi discuss impact
publish inaugur quarterli valuat report analysi med-tech name broken five market cap group
detail deep dive report includ trend graph comparison tabl rang financi valuat
metric five year vs low base datapoint rough math suggest forward p/
entir sector higher vs low price-to-earnings multipl large/mid-cap higher
data continu showcas tavr benefit surgeri
sunday morn conjunct virtual confer edward releas data remind
evalu non-inferior vs surgeri follow-up expect continu ten year data taken
aggreg paint favor pictur low-risk ssa cohort although signal caught attent highlight
talk compani especi sinc gone virtual light coronaviru
pandem importantli await data pascal trial state along pascal biggest call option
stori signific valu driver move ahead
takeaway discuss manag
discuss potenti near-term impact manag key takeaway relat
risk mitig plan place registr monotherapi arm krystal still track
report durabl data nsclc patient year-end combin arm
antibodi potenti subject reduc patient flow iv infus sitravatinib may impact reduc
patient enrol sapphir studi recent discuss suggest registr data
potenti nda file base view impact lower sale estim
sitravatinib drive new price target maintain outperform
updat analysi clinic trial identifi new area focu potenti medic advanc
impress rapid expans number trial type intervent divers sponsor
geographi studi investor becom increasingli focus macro factor drive broader market dynam
suspect clinic trial trend could provid insight effort made stem tide
especi interest studi anti-vir approach provid direct therapeut intervent sars-
viru believ drug success could provid immedi impact largest number
patient biotech research host call week provid addit insight includ
interview dr jay luli ceo challeng discov develop anti-vir drug
takeaway kol discuss impact oncolog
discuss impact oncolog practic clinic trial dr corcoran md phd massachusett
gener hospit cancer center dr chung md phd stanford univers trial still enrol despit skeleton
crew driven drug deem viabl option late line patient prefer given oral vs iv agent
demonstr efficaci potenti signific benefit soc trial modifi includ telemedicin local
scan trial intervent long hospit stay incl cart bmt biopsi intens pk/pd work delay
site trial delay may reach nine month beyond trial new patient volum procedur
delay possibl exist patient visit postpon dose interv may prolong
prefer oral may increas crisi goe much longer choos tki vs iv option
pandem influenc program mix bag
spoke management discuss impact oper develop timelin although sale forc
temporarili virtual management reiter prior guidanc tibsovo sale principl
pandem could encourag prescrib choos oral avail therapi aml believ slowdown new
script inevit model sale fall slightli guidanc agio adequ stockpil
tibsovo weather short-term suppli chain disrupt one year suppli drug year api
hand patient recruit on-going trial mitapivat may experi delay believ key catalyst includ
top-lin data activ activate-t studi remain intact reiter perform
apr confer call confer call dr andrew colin
may oppenheim med-tech day san francisco ca
may biotech summit featur chemistri life process institut
juli montauk summit emerg life scienc
sept fall summit focus specialti pharma diseas gene therapi new york ny
oct houston oncolog summit md anderson cancer center
healthcar provid manag
